Showing 1672 results
-
Press release /
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Divested assets to include Xiidra®, on-market treatment for dry eye disease and SAF312 (libvatrep), potential therapy for chronic ocular surface painDeal consistent with Novartis focused strategy of… -
Press release /NijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions Point of care in office…
-
Press release /Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development…
-
Press release /At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase…
-
Press release /New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline…
-
Press release /Collaboration to address product development and scale up challenges posed by current pandemic Basel, March 26, 2020 — Today, Novartis and a consortium of life sciences companies announced an…
-
Press release /The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally A…
-
Press release /New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patientsCrizanlizumab, a monthly infusion…
-
Press release /Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy …
-
Press release /Post-hoc analysis of PARADIGM-HF published in JAMA Cardiology shows heart failure patients treated with Entresto experience significant improvements in physical and social activities compared to…